Low-dose levothyroxine reduces intrahepatic lipid content in patients with type 2 diabetes mellitus and NAFLD
10.1210/jc.2018-00475
Saved in:
Main Authors: | Bruinstroop E., Dalan R., Cao Y., Bee Y.M., Chandran K., Cho L.W., Soh S.B., Teo E.K., Toh S.-A., Leow M.K.S., Sinha R.A., Sadananthan S.A., Michael N., Stapleton H.M., Leung C., Angus P.W., Patel S.K., Burrell L.M., Lim S.C., Sum C.F., Velan S.S., Yen P.M. |
---|---|
Other Authors: | DEAN'S OFFICE (SSH SCH OF PUBLIC HEALTH) |
Format: | Article |
Published: |
Oxford University Press
2020
|
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/177756 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Thyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD
by: Sinha, R.A, et al.
Published: (2020) -
Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression
by: Bruinstroop, E, et al.
Published: (2022) -
Visceral adipose tissue tracks more closely with metabolic dysfunction than intrahepatic triglyceride in lean Asians without diabetes
by: Ding C., et al.
Published: (2020) -
Smart polymeric nanofibers for topical delivery of levothyroxine
by: Azarbayjani, A.F., et al.
Published: (2014) -
Do thyroid-stimulating hormone, body weight, or body mass index serve as adequate markers to guide levothyroxine dose titration?
by: Dietrich J.W., et al.
Published: (2020)